Thank you for Subscribing to Cannabis Business Insights Weekly Brief
Cannabis Business Insights: Specials Magazine
CANNFX, the premium brand of Ampyl Sciences, was founded with a visionary focus on providing patients globally with the highest quality NZ-grown pharmaceutical-grade medicinal cannabis. Every dried flower is cultivated indoors under strict controls, one carefully grown bud at a time. Having just returned from picking up a shipment for export from a cultivator near one of the purest water springs in the southern hemisphere, founder and CEO Bastiaan Kramer reflects on how this trip represents the company’s mission. Providing premium cannabis flower from plant to patient. New Zealand is known for its rigorous medicinal cannabis regulations. The country mandates tight pesticide controls, has the strictest microbial testing in the world and there is no irradiation. These are requirements that CANNFX has embedded into its DNA, and in collaboration with its cultivators, became the first company to successfully export NZ-grown medicinal cannabis flower to the EU and UK.
Cannabis Consulting Services 2025
The adult use (recreational) and medicinal cannabis markets are brimming with opportunities for those ready to dive in. In this highly regulated, dynamic industry, having the right strategic partner for maximizing your cannabis business potential through professional consultation from concept to commence operations can make all the difference in becoming a successful operator. Tenax Strategies (Tenax), a cannabis consulting and government affairs firm, emerges as the strategic partner for cannabis entrepreneurs looking to start a business or expand their existing business. Tenax offers end-to-end project management solutions for various cannabis businesses, including retail dispensaries, cultivation, product manufacturing, and delivery. Tenax’s tagline, ‘Get Licensed. Get Open.’ encapsulates its commitment to driving success for its clients. Regardless of the licensing requirements or market conditions, Tenax Strategies covers all aspects of the cannabis business lifecycle. From the moment an entrepreneur decides to enter the cannabis industry, Tenax offers a clear roadmap to success through its robust strategic planning and consulting capabilities. This includes providing project management throughout the entire process of site selection, securing state and local permits and licenses, navigating state and municipal regulations, and ensuring compliance even in the post-operational phase of the operation. “We support cannabis clients with end-to-end project management, guiding them from site selection to licensing through their exit strategy and beyond,” says Greg D’Agostino, Partner. Since 2012, Tenax Strategies has led the way in cannabis regulation, state licensing and municipal permitting, beginning with the Massachusetts' medical marijuana regulations. Tenax’s extensive experience has led them to establish a broad network of strategic partners in the industry that includes architects, engineers, attorneys, as well as nearly all of the necessary partners required to open and operate your cannabis business. This enables Tenax to provide comprehensive cannabis consulting services across many states and municipalities, all with diverse regulatory landscapes.
CXO INSIGHTS
Securing Our Food Future
Frances Tolson, Product Development Manager, Rijk Zwaan
The New Age of Medical Affairs
Dr Sarah Tregenza, PhD BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre, and Matthew Britland, Founder and Medical Director, MedWise Consulting
Translating Research into Relief
Suci Ameliya Reza Zairizal, Associate Manager, Novugen Pharma
Building Better Health Through Innovation and Leadership
Lotus Mallbris, Senior Vice President, Business Unit Leader - Immunology Japan, Eli Lilly and Company
Emphasizing the Importance of Assuring Product Quality
Raymond R. Tjandrawinata, Director of Business Development and Scientific Affairs, Dexa Medica
Insights into Healthcare Ecosystem
Wataru Momose, Ph.D., Director of Anti-Tuberculosis Project (Global TB project), Otsuka Pharmaceutical Co., Ltd
Halal Biopharma: Closing the Therapeutic Gaps
Dr. Israfil Merican, MD, MHM, Vice President - Head of Biopharma and Patient Access, Pharmaniaga Berhad
IN FOCUS
CBD, Hemp, and the Rise of Natural Living in APAC
The Asia-Pacific region is shifting towards embracing cannabis, particularly CBD, in mainstream health and lifestyle sectors, presenting both opportunities and challenges amid evolving regulations.
EDITORIAL
Elevating Care through Cannabis Innovation
As patient expectations evolve as the limitations of conventional treatments become increasingly evident, medicinal cannabis is shifting from alternative therapy to a central component of modern, patient-centered care. Across clinical settings, specialized cannabis therapeutics are now essential tools in managing chronic pain, neurological disorders, oncology symptoms and mental health conditions. To meet this growing demand, leading medicinal cannabis organizations follow precision cultivation, pharmaceutical-grade formulation, rigorous testing, clinical education and ongoing patient support. Technology accelerates this growth. AI-powered dosing engines, real-world evidence platforms and digital engagement tools enable more personalized treatment, continuous monitoring and measurable improvements in therapeutic outcomes. These innovations give healthcare providers greater confidence in prescribing and help patients receive care that is data-driven and tailored to their individual needs. This edition of Cannabis Business Insights APAC explores how highperforming medicinal cannabis organizations are transforming integrative care into a disciplined, technology-enabled and outcomes-focused field. Featured thought leaders include Wataru Momose, director of antituberculosis project (Global TB project) at Otsuka Pharmaceutical Co., Ltd., who highlights the integration of AI, preventive care and continuous production systems in biopharmaceutical manufacturing as key strategies for reducing medical costs and improving quality of life. Raymond R. Tjandrawinata, director of business development and scientific affairs at DexaMedica, advocates a quality assurance approach built on certified sourcing, rigorous testing, traceable documentation and adherence to international standards. The magazine also spotlights leaders like CANNFX (by Ampyl Sciences), a New Zealand–based medicinal cannabis brand, exporting highgrade, non-irradiated dried flower globally. Partnered with top cultivators, it ensures certified quality and consistent pharmacological standards. We hope this edition offers valuable insight into how medicinal cannabis is reshaping the future of clinical care, expanding treatment options and raising the standard for patient outcomes.
